Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pazopanib + FOLFOX6
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral (pazopanib), Intravenous (FOLFOX6: Oxaliplatin, Folinic Acid, Fluorouracil)
01
Overview
**Pazopanib + FOLFOX6** is a combination regimen for the treatment of advanced or metastatic colorectal cancer, involving oral pazopanib (a multi-targeted tyrosine kinase inhibitor) together with the FOLFOX6 chemotherapy regimen (folinic acid/leucovorin, fluorouracil [5-FU], and oxaliplatin). Pazopanib targets vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFRA/PDGFRB), and c-Kit, inhibiting angiogenesis. FOLFOX6 is a cytotoxic chemotherapy protocol primarily affecting DNA synthesis and cell division by combining a platinum agent (oxaliplatin), a pyrimidine analog (fluorouracil), and folinic acid to enhance fluorouracil activity. This combination is investigated to improve treatment efficacy by co-targeting tumor vasculature and cell replication mechanisms[1][3][5].
- Brand names
- Votrient
- Other names
- pazopanib + FOLFOX6pazopanib + folinic acid + fluorouracil + oxaliplatin
02
Targets
OATP1B1 (Organic anion transporting polypeptide 1B1)KIT (c-KIT proto-oncogene receptor tyrosine kinase)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)CSF1R (Macrophage colony-stimulating factor receptor)LCK (Proto-oncogene tyrosine-protein kinase Lck)VEGFR3 (Vascular endothelial growth factor receptor 3)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)ITK (Interleukin 2-inducible T-cell kinase)DNAVEGFR-1 (Vascular endothelial growth factor receptor 1)UGT1A1 (UDP-glucuronosyltransferase 1A1)PDGFRA (Platelet-derived growth factor receptor alpha)BRAF (B-Raf proto-oncogene, serine/threonine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on pazopanib + FOLFOX6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pazopanib + FOLFOX6.